Drug Evaluation, Preclinical

"Drug Evaluation, Preclinical" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Preclinical testing of drugs in experimental animals or in vitro for their biological and toxic effects and potential clinical applications.

Descriptor ID	D004353
MeSH Number(s)	E05.295.750 E05.337.550
Concept/Terms	Drug Evaluation, Preclinical Drug Evaluation, Preclinical Drug Evaluations, Preclinical Drug Screening Drug Screenings Screening, Drug Screenings, Drug Evaluation Studies, Drug, Pre-Clinical Preclinical Drug Evaluations Evaluation, Preclinical Drug Evaluations, Preclinical Drug Preclinical Drug Evaluation Drug Evaluation Studies, Preclinical Evaluation Studies, Drug, Preclinical Medicinal Plants Testing, Preclinical Medicinal Plants Testing, Preclinical

Below are MeSH descriptors whose meaning is more general than "Drug Evaluation, Preclinical".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Drug Discovery [E05.295]
Drug Evaluation, Preclinical [E05.295.750]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]

Below are MeSH descriptors whose meaning is related to "Drug Evaluation, Preclinical".

Below are MeSH descriptors whose meaning is more specific than "Drug Evaluation, Preclinical".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Drug Evaluation, Preclinical" by people in this website by year, and whether "Drug Evaluation, Preclinical" was a major or minor topic of these publications.

Bar chart showing 79 publications over 23 distinct years, with a maximum of 9 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1999	0	2	2
2000	0	1	1
2001	0	2	2
2002	0	2	2
2003	0	1	1
2004	0	7	7
2005	0	4	4
2006	1	5	6
2007	2	4	6
2008	1	4	5
2009	1	1	2
2010	2	4	6
2011	6	3	9
2012	1	3	4
2013	0	4	4
2014	1	2	3
2015	1	3	4
2016	1	1	2
2017	0	3	3
2018	0	3	3
2020	0	1	1
2023	0	1	1

Below are the most recent publications written about "Drug Evaluation, Preclinical" by people in Profiles.

Guo T, Zou X, Sundar S, Jia X, Dhong C. In situ measurement of viscoelastic properties of cellular monolayers via graphene strain sensing of elastohydrodynamic phenomena. Lab Chip. 2023 09 13; 23(18):4067-4078.

View in: PubMed
Di Diego JM, Patocskai B, Barajas-Martinez H, Borb?th V, Ackerman MJ, Burashnikov A, Clatot J, Li GR, Robinson VM, Hu D, Antzelevitch C. Acacetin suppresses the electrocardiographic and arrhythmic manifestations of the J wave syndromes. PLoS One. 2020; 15(11):e0242747.

View in: PubMed
Woody MS, Greenberg MJ, Barua B, Winkelmann DA, Goldman YE, Ostap EM. Positive cardiac inotrope omecamtiv mecarbil activates muscle despite suppressing the myosin working stroke. Nat Commun. 2018 09 21; 9(1):3838.

View in: PubMed
Perepelyuk M, Sacko K, Thangavel K, Shoyele SA. Evaluation of MUC1-Aptamer Functionalized Hybrid Nanoparticles for Targeted Delivery of miRNA-29b to Nonsmall Cell Lung Cancer. Mol Pharm. 2018 03 05; 15(3):985-993.

View in: PubMed
Marrone L, Poser I, Casci I, Japtok J, Reinhardt P, Janosch A, Andree C, Lee HO, Moebius C, Koerner E, Reinhardt L, Cicardi ME, Hackmann K, Klink B, Poletti A, Alberti S, Bickle M, Hermann A, Pandey UB, Hyman AA, Sterneckert JL. Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology that Is Rescued by Drugs Inducing Autophagy. Stem Cell Reports. 2018 02 13; 10(2):375-389.

View in: PubMed
Tsonkova VG, Sand FW, Wolf XA, Grunnet LG, Kirstine Ringgaard A, Ingvorsen C, Winkel L, Kalisz M, Dalgaard K, Bruun C, Fels JJ, Helgstrand C, Hastrup S, ?berg FK, Vernet E, Sandrini MPB, Shaw AC, Jessen C, Gr?nborg M, Hald J, Willenbrock H, Madsen D, Wernersson R, Hansson L, Jensen JN, Plesner A, Alanentalo T, Petersen MBK, Grapin-Botton A, Honor? C, Ahnfelt-R?nne J, Hecksher-S?rensen J, Ravassard P, Madsen OD, Rescan C, Frogne T. The EndoC-?H1 cell line is a valid model of human beta cells and applicable for screenings to identify novel drug target candidates. Mol Metab. 2018 02; 8:144-157.

View in: PubMed
Yang H, Yang C, Wang Y, Rhodes G, Robinson M, Cheng G, Qi X, Mo H, Tian Y, Pakdaman R, Sheng XC, Kim CU, Delaney WE. Preclinical characterization of the novel HCV NS3 protease inhibitor GS-9256. Antivir Ther. 2017; 22(5):413-420.

View in: PubMed
Shah AN, Cristofanilli M. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. Curr Treat Options Oncol. 2017 01; 18(1):6.

View in: PubMed
Carr R, Schilling J, Song J, Carter RL, Du Y, Yoo SM, Traynham CJ, Koch WJ, Cheung JY, Tilley DG, Benovic JL. ?-arrestin-biased signaling through the ?2-adrenergic receptor promotes cardiomyocyte contraction. Proc Natl Acad Sci U S A. 2016 07 12; 113(28):E4107-16.

View in: PubMed
Oppermann S, Ylanko J, Shi Y, Hariharan S, Oakes CC, Brauer PM, Z??iga-Pfl?cker JC, Leber B, Spaner DE, Andrews DW. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells. Blood. 2016 08 18; 128(7):934-47.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement